IRIS PubliCatt

Guidi, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.257
EU - Europa 2.256
AS - Asia 386
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
Totale 4.913
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.247
DE - Germania 933
SE - Svezia 440
CN - Cina 259
UA - Ucraina 235
IT - Italia 177
FR - Francia 124
IE - Irlanda 119
GB - Regno Unito 91
IN - India 67
FI - Finlandia 48
PL - Polonia 32
TR - Turchia 26
BE - Belgio 20
IR - Iran 13
CA - Canada 8
NL - Olanda 8
CI - Costa d'Avorio 7
JP - Giappone 7
HK - Hong Kong 6
CZ - Repubblica Ceca 4
ES - Italia 4
PT - Portogallo 4
BG - Bulgaria 3
CH - Svizzera 3
GR - Grecia 3
HU - Ungheria 3
SG - Singapore 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BR - Brasile 2
BZ - Belize 2
PH - Filippine 2
TW - Taiwan 2
AL - Albania 1
DK - Danimarca 1
EU - Europa 1
NO - Norvegia 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
VE - Venezuela 1
VN - Vietnam 1
Totale 4.913
Salva come PNG Salva come JPEG
Città #
Chandler 545
Ashburn 176
Jacksonville 166
San Mateo 119
Dublin 116
Dearborn 107
Ann Arbor 101
New York 89
Nanjing 71
Wilmington 61
Cattolica 59
Nürnberg 59
Boston 48
Milan 41
Munich 41
Bremen 34
Princeton 34
Beijing 32
Lawrence 32
Houston 29
Izmir 26
Marseille 24
Lancaster 22
Fairfield 21
Kraków 21
Nanchang 20
Seattle 19
Woodbridge 19
Brussels 18
Redwood City 18
Shenyang 16
Hangzhou 15
Augusta 14
Changsha 14
Leawood 13
Boardman 12
Mountain View 12
Hebei 11
Jiaxing 11
Los Angeles 11
Warsaw 11
Detroit 9
Kunming 9
Norwalk 9
Pune 9
Redmond 9
Tianjin 9
Zhengzhou 9
Ardabil 8
Costa Mesa 8
Shanghai 8
Abidjan 7
Andover 7
Cagliari 7
Guangzhou 7
University Park 7
Fremont 6
San Jose 6
Washington 6
Hefei 5
Helsinki 5
Jinan 5
Sacramento 5
Hong Kong 4
Indiana 4
Kish 4
Millbury 4
Rome 4
Toronto 4
Bengaluru 3
Brno 3
Cambridge 3
Edinburgh 3
Lanzhou 3
London 3
San Diego 3
Simi Valley 3
Sofia 3
Tokyo 3
A Coruña 2
Amsterdam 2
Belize City 2
Berlin 2
Budapest 2
Central 2
Changchun 2
Chicago 2
Chiswick 2
Gunzenhausen 2
Henderson 2
Lappeenranta 2
Las Vegas 2
Lille 2
Monmouth Junction 2
Montreal 2
Mumbai 2
Napoli 2
Paris 2
Pavia 2
Phoenix 2
Totale 2.564
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 313
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 147
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 137
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 136
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 131
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 130
Early atherosclerosis in patients with inflammatory bowel disease. 128
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 127
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 126
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 116
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 113
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 112
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 108
Sonography of the small bowel after oral administration of fluid: an assessment of the diagnostic value of the technique 107
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 100
Ileal Crohn's disease: CEUS determination of activity 98
Use of infliximab in particular clinical settings: management based on current evidence. 94
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 92
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 92
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 91
Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy 90
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 86
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 85
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 83
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 81
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 79
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 76
Management of perianal fistulas in Crohn's disease: an up-to-date review 69
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 69
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 66
AID in aging and autoimmune diseases 65
Mucosal healing in ulcerative colitis: surveillance or colectomy? 63
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 62
Adalimumab in active ulcerative colitis: a "real-life" observational study 62
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 60
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 60
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 56
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 56
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 53
Neuropeptide Y plasma levels and immunological changes during academic stress 52
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 51
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 50
[Soluble factors with immunosuppressive activity in human neoplasms] 49
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 49
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 48
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 48
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 47
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 46
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 46
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 45
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 44
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 43
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 43
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 42
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. 37
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 37
Watery stools and metabolic acidosis 37
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 36
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 36
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 35
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 34
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 33
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 33
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 33
Linking estrogen receptor β expression with inflammatory bowel disease activity 32
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 26
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 20
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis 9
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience 9
Serum levels of metalloproteinases and their inhibitors in nonalcoholic steatohepatitis 7
Small bowel diseases 3
Small bowel diseases 1
Totale 4.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.004
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.004
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019126 0 0 0 0 0 0 0 0 0 32 58 36
2019/2020738 132 35 66 27 52 109 62 31 55 23 102 44
2020/2021478 21 48 15 56 59 11 44 17 59 17 117 14
2021/2022634 55 45 9 107 16 13 8 113 17 25 103 123
2022/20231.352 180 191 95 230 106 158 51 110 170 10 33 18
2023/2024499 30 182 18 46 17 112 25 38 9 22 0 0
Totale 4.980